Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks regarding the promising potential of TT fields (Tumor Treating Fields) as a treatment modality for cancer patients.
When asked about patient subgroups that might benefit more or less from TT field treatment, Dr. Leal responded with a wealth of knowledge and confidence. "I think, from the results of the Lunar trial," she began, "what we saw was a striking improvement in overall survival in the ICI-treated subgroups." She went on to elaborate, emphasizing the significance of combining immune checkpoint inhibitors (ICI) with TT fields. "In the ICI treated subgroups, the median overall survival was 18.5 months in the TT fields plus ICI versus 10.8 months in the ICI alone group with a hazard ratio here of 0.63 and a P value of 0.03."
Learn more by watching the full video.
Check the full interview with Ticiana Leal, MD here.